Brazil · Delayed Price · Currency is BRL Hypera Earnings Call Transcripts
Fiscal Year 2026
-
Q3 revenue rose 9.4% YoY and sell-out outpaced the market, with Semavy driving momentum. EBITDA conversion reached 97.5%, while net debt fell to BRL 5.6bn; management prioritized deleveraging and expects CapEx to decline as projects conclude.
-
Q2 2026 saw robust revenue, EBITDA, and net income growth, with strong cash flow and reduced net debt. New launches in GLP-1 and women's health are set to drive future growth, while working capital and margin improvements are expected to continue.
-
Q1 2026 saw 87% revenue growth and 9.5% sell-out increase, driven by new launches and logistics gains. Net debt fell nearly 20% after a BRL 1.5 billion capital increase, with strong cash flow and margin performance. Outlook remains positive, with further launches and inventory optimization expected.
Fiscal Year 2025
-
Sellout grew 6.8% in 2025, with net revenue up 3.4% and record operating cash flow after working capital optimization. Entering 2026, the company expects further efficiency gains, strong cash flow, and growth from new launches, especially semaglutide, pending regulatory approval.
-
Net revenue rose 16% year-over-year to BRL 2.2 billion, with EBITDA margin at 34% and record operational cash flow. Retail outperformed the market, while institutional sales declined; strong pipeline and new launches are expected to drive future growth.
-
Sell-out grew 5.5% in Q2 2025, outpacing the market, with strong acceleration in May–July. Working capital optimization improved efficiency and margins, while net revenue reached R$2.2 billion and EBITDA margin was 33.7%. Focus remains on deleveraging and sustainable growth.
-
Sell-out grew 7% in Q1 2025, but net revenue fell 41% due to working capital optimization, resulting in negative EBITDA and net earnings. Operational cash flow hit a record, and margins are expected to normalize from Q2 as new product launches and efficiency measures take effect.
Fiscal Year 2024
-
Sell-out grew 9% in 2024, but net revenue fell 6% due to working capital optimization, with margins and net income also down. Over 50 new products were launched, and significant investments were made in marketing, R&D, and capacity. Margin recovery and normalized operations are expected in H2 2024.
-
Sell-out growth accelerated to 11% in Q3 2024, driven by flu and seasonal product demand normalization. Despite lower revenue and income from working capital optimization, gross margin stayed near 60% and free cash flow rose 23%, reducing net debt. Inventory and marketing investments are being optimized for future growth.
-
A new working capital strategy aims to boost cash generation by BRL 2.5 billion by 2028 and BRL 7.5 billion over ten years, with a gradual reduction in receivables and inventories. Short-term financial impacts are expected, but operational efficiency and shareholder value are set to improve from 2026.
-
Q2 2024 saw 6.3% sell-out growth, record cash flow, and strong performance in chronic treatments, offsetting weak influenza sales. Guidance for 2024 is reaffirmed, with H2 expected to benefit from market recovery and new product launches.